AS03B-adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: a Phase 2/3 Randomized, Placebo-controlled, Observer-blinded Trial

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2014 Oct 9

PMID 25293368

Citations 11

Authors

Pope Kosalaraksa

Robert Jeanfreau

Louise Frenette

Mamadou Drame

Miguel Madariaga

Bruce L Innis

Olivier Godeaux

Patricia Izurieta

David W Vaughn

Affiliations

Soon will be listed here.

Abstract

Background: This phase 2/3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicity, and safety of an inactivated, split-virion H5N1 influenza vaccine (A/Indonesia/5/2005) in children aged 6 months through 17 years.

Methods: Children received 2 influenza vaccine doses 21 days apart, each containing 1.9 µg of hemagglutinin and AS03B adjuvant (5.93 mg of α-tocopherol). The randomization ratio was 8:3 for vaccine to placebo, with equal allocation between 3 age strata (6-35 months, 3-8 years, and 9-17 years). Immunogenicity against the vaccine strain was assessed 21 days after the first and second vaccine doses for all vaccinees, at day 182 for half, and at day 385 for the remaining half. Reactogenicity after each dose and safety up to 1 year after vaccination were evaluated.

Results: Within each age stratum, the lower limit of the 98.3% confidence interval for the day 42 seroprotection rate was ≥70%, thus fulfilling the US and European licensure criteria. The immune responses elicited by vaccine persisted well above baseline levels for 1 year. The vaccine was more reactogenic than placebo, but no major safety concerns were identified.

Conclusions: AS03B-adjuvanted H5N1 influenza vaccine was immunogenic and showed an acceptable safety profile in all age groups studied. Clinical Trials Registration: NCT01310413.

Citing Articles

Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art.

Focosi D, Maggi F Int J Mol Sci. 2024; 25(15).

PMID: 39126117 PMC: 11312817. DOI: 10.3390/ijms25158550.

Inactivated and live-attenuated seasonal influenza vaccines boost broadly neutralizing antibodies in children.

Yegorov S, Celeste D, Braz Gomes K, Ang J, Vandenhof C, Wang J Cell Rep Med. 2022; 3(2):100509.

PMID: 35243417 PMC: 8861809. DOI: 10.1016/j.xcrm.2022.100509.

"World in motion" - emulsion adjuvants rising to meet the pandemic challenges.

OHagan D, van der Most R, Lodaya R, Coccia M, Lofano G NPJ Vaccines. 2021; 6(1):158.

PMID: 34934069 PMC: 8692316. DOI: 10.1038/s41541-021-00418-0.

Prevention of Emerging Infections in Children.

Puthanakit T, Anugulruengkitt S, Jantarabenjakul W Pediatr Clin North Am. 2021; 69(1):185-202.

PMID: 34794674 PMC: 8592647. DOI: 10.1016/j.pcl.2021.08.006.

Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.

Nachbagauer R, Salaun B, Stadlbauer D, Behzadi M, Friel D, Rajabhathor A NPJ Vaccines. 2019; 4:51.

PMID: 31839997 PMC: 6898674. DOI: 10.1038/s41541-019-0147-z.

References

Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R . Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004; 103(1-2):163-71. DOI: 10.1016/j.virusres.2004.02.029. View

Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J . AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012; 7(3):e33536. PMC: 3314666. DOI: 10.1371/journal.pone.0033536. View

Han F, Lin L, Warby S, Faraco J, Li J, Dong S . Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011; 70(3):410-7. DOI: 10.1002/ana.22587. View

Rumke H, Bayas J, de Juanes J, Caso C, Richardus J, Campins M . Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008; 26(19):2378-88. DOI: 10.1016/j.vaccine.2008.02.068. View

Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche M, Denis M . Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2009; 375(9708):41-8. DOI: 10.1016/S0140-6736(09)62026-2. View

Miller E, Andrews N, Stellitano L, Stowe J, Winstone A, Shneerson J . Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013; 346:f794. DOI: 10.1136/bmj.f794. View

Oner A, Dogan N, Gasimov V, Adisasmito W, Coker R, Chan P . H5N1 avian influenza in children. Clin Infect Dis. 2012; 55(1):26-32. DOI: 10.1093/cid/cis295. View

Heier M, Gautvik K, Wannag E, Bronder K, Midtlyng E, Kamaleri Y . Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 2013; 14(9):867-71. DOI: 10.1016/j.sleep.2013.03.020. View

Rowe T, Abernathy R, Thompson W, Lu X, Lim W, Fukuda K . Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999; 37(4):937-43. PMC: 88628. DOI: 10.1128/JCM.37.4.937-943.1999. View

10.

Nolan T, Richmond P, Formica N, Hoschler K, Skeljo M, Stoney T . Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine. 2008; 26(50):6383-91. DOI: 10.1016/j.vaccine.2008.08.046. View

11.

Stephenson I, Wood J, Nicholson K, Charlett A, Zambon M . Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004; 103(1-2):91-5. DOI: 10.1016/j.virusres.2004.02.019. View

12.

Leroux-Roels G . Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther. 2009; 9(8):1057-71. DOI: 10.1517/14712590903066695. View

13.

Dauvilliers Y, Arnulf I, Lecendreux M, Charley C, Franco P, Drouot X . Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013; 136(Pt 8):2486-96. DOI: 10.1093/brain/awt187. View

14.

Langley J, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G . Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis. 2010; 201(11):1644-53. DOI: 10.1086/652701. View

15.

Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M . Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010; 375(9720):1100-8. DOI: 10.1016/S0140-6736(09)62126-7. View

16.

Diez-Domingo J, Garces-Sanchez M, Baldo J, Planelles M, Ubeda I, JuBert A . Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J. 2010; 29(6):e35-46. DOI: 10.1097/INF.0b013e3181daf921. View

17.

Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P . AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010; 51(6):668-77. DOI: 10.1086/655830. View

18.

Marcy S, Kohl K, Dagan R, Nalin D, Blum M, Jones M . Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004; 22(5-6):551-6. DOI: 10.1016/j.vaccine.2003.09.007. View

19.

Szakacs A, Darin N, Hallbook T . Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013; 80(14):1315-21. DOI: 10.1212/WNL.0b013e31828ab26f. View

20.

Pyhala R, Kumpulainen V, Alanko S, Forsten T . HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine. 1994; 12(10):947-52. DOI: 10.1016/0264-410x(94)90039-6. View